world-optometry-2017-keynote

2 / 7

Page 28
conferenceseries.com
July 17-19, 2017 Chicago, USA
World Congress and Expo on
Optometry & Vision Science
Volume 2, Issue 1 (Suppl) Optom Open Access, an open access journal
ISSN:2476-2075 World Optometry 2017
July 17-19, 2017
Trans-scleral cyclophotocoagulation for the treatment of glaucoma
Introduction: This project was undertaken to assess the clinical value of using a new transscleral cyclophotocoagulation device
in patients with mild to severe glaucoma including those who have unsuccessfully undergone other procedures. This is a one
year update of earlier reported data.
Method: This is a single site review of 26 eyes of 20 patients, 4 eyes were classified as mild glaucoma, 5 as moderate and 18
as severe or end stage glaucoma. Two eyes of one patient were lost to follow up. All eyes but 3 had previously undergone
phacoemulsification and SLT or MLT. 4 eyes had previously undergone trabeculectomy.
Results: Patients undergoing the procedure had an average IOP of 25.6 and were on an average of 3 IOP lowering meds. After
the procedure, patients were started on difluprednate hourly for the first day then tapered over 3 weeks. Average IOP drop at
POD 1 was 20% and 34% at pod7 (using an average 1.3 IOP lowering meds). At POD14, average IOP from baseline was 8%
using one IOP lowering medication. At one month, IOP was down by 20% and average number of IOP reducing medications
was 1.2. At 6-12 months, the average IOP lowering was 30% compared with baseline IOP on and average of 1.8 medications.
There were no serious adverse events.
Conclusion: Patients with glaucoma of varying severities are able to safely undergo transscleral cyclophotocoagulation. On
average, IOPs were reduced by 30% over one year’s time and number of IOP lowering medications was reduced by 60%.
Further study is required to determine ideal treatment guideliness.
Biography
Rolando Toyos is an American Physician and Medical Director who specializes in Ophthalmology. He developed the use of intense pulsed light for the treatment of dry eye
conditions such as meibomian gland dysfunction.
Ronaldo Toyos
Toyos Clinic, USA
Ronaldo Toyos, Optom Open Access 2017, 2:1 (Suppl)
DOI: 10.4172/2476-2075-C1-001
Notes: